ClinicalTrials.gov
ClinicalTrials.gov Menu

ATM Variants in Radiotherapy Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00214227
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : June 19, 2013
Sponsor:
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
The purpose of this study is to compare the baseline incidence of variant alleles in the ATM and/or other DNA repair genes present in the Native American population versus the non-Native American population. It is thought that a higher baseline incidence of the variant alleles in the ATM gene may correlate to higher rates and higher grades of radiation toxicities noted in the Native American population.

Condition or disease
Radiotherapy

Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: ATM Variants in Radiotherapy
Study Start Date : December 2007
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013



Primary Outcome Measures :
  1. to determine baseline incidence of variant alleles in ATM [ Time Frame: one blood draw ]
    to determine the baseline incidence of variant alleles in ATM resent in the population of Native americans with cancer who are undergoing radiation therapy to a similar group of non-native americans who have undergone or are undergoing raditohterapy


Secondary Outcome Measures :
  1. to compare the baseline incidence of variant alleles in ATM [ Time Frame: one blood draw ]
    to compare the baseline incidence of variant alleles in ATM resent in the population of Native americans with cancer who are undergoing radiation therapy to a similar group of non-native americans who have undergone or are undergoing raditohterapy


Biospecimen Retention:   Samples With DNA
direct sequence analysis of all exons and intron-exon junctions of the ATM gene. DNA will be isolated from lympocytes using the PAX blood DNA system.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who have been enrolled on RO02803.
Criteria

Inclusion Criteria:

  • Indication for radiotherapy.
  • Ability or desire to donate a blood sample and be followed closely for radiation toxicities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214227


Locations
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Investigators
Principal Investigator: Mark Ritter, MD, PhD University of Wisconsin, Madison

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00214227     History of Changes
Other Study ID Numbers: RO05305
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: June 19, 2013
Last Verified: June 2013

Keywords provided by University of Wisconsin, Madison:
patient who will undergo definitive radiotherapy